NCT07177209Active, not recruiting
Describing Treatment Patterns and Creating an Updated Treatment Flow in an Ulcerative Colitis Population
DESCRIBING PRESCRIPTION PATTERNS IN AN ULCERATIVE COLITIS POPULATION AND GENERATING AN UPDATED ULCERATIVE COLITIS TREATMENT PARADIGM
Source: ClinicalTrials.gov · Last updated 15 Oct 2026
Brief summary (registry, in English)
Describing Treatment Patterns and Creating an Updated Treatment Flow in an Ulcerative Colitis Population
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 4000 (actual)
- First submitted
- 1 Aug 2025
- Start date
- 1 Apr 2026
- Primary completion date
- 30 Oct 2026
- Lead sponsor
- Pfizer
- Diseases
- Ulcerative colitis
- NCT number
- NCT07177209
What you commit to
- Study type: Observational
- Participants enrolled: 4000
- From 1 Apr 2026 to the primary completion date, 30 Oct 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Criteria the registry did not label
- Patients must meet all of the following inclusion criteria to be eligible for inclusion in the study:
- Patient enrolled in IBD registry from 2009
- \>18 years at time of diagnosis.
- Diagnosis of Ulcerative Colitis.
- Patient data entered during the study period.
- Minimum duration of data post UC diagnosis (Cohort A: 6 months, Cohort B-D 6 months)
Age in the registry: 19 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Pfizer Coordinator of this site? Confirm its status | Tadworth | United Kingdom | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.